Skip to content

To study the enhanced effect of the combination of low-dose Methadone with Morphine in pain management for Gastrointestinal cancer patients when compared to Morphine alone for pain management in Gastrointestinal cancers

Evaluating the efficacy of combination of low dose Methadone with Morphine vs Morphine for pain management in Gastrointestinal cancers- a Randomised Control Trial - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082707
Enrollment
74
Registered
2025-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C15-C26- Malignant neoplasms of digestive organs

Interventions

Intervention1: Evaluation of efficacy of combination of low dose oral Methadone syrup with Morphine tablets for pain in patients of Gastrointestinal cancers.: Analgesic optimization with the combinati

Sponsors

Dr BRA IRCH , All India institute of Medical Sciences, New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 18 and 65 years Patients with the diagnosis of Gastrointestinal cancers with abdominal pain on opioids Patients for whom the pain is not adequately managed which is NRS less than 4 with 60 mg of Morphine per day are recruited into the study Patient with the ability to provide informed consent and is willing to comply with study procedure and follow up visits and recruited into the study Patients belonging to ECOG physical status classification I II and III are recruited into the study

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to Methadone like (Hypersensitivity, Acute or Severe bronchial asthma, Paralytic ileus, Uncontrolled mental illness, Pregnancy, Severe Hepatic impairment, History of conduction heart disorders, significant arrhythmias, heart block). 2. Inability to provide informed consent or comply with study procedures. 3. Patient taking other opioids like Fentanyl. 4. Patients who are on drugs which causes QTc prolongation (Antimalarials, Moxifloxacin, Antidepressants, Antipsychotics , Antiarrhythmics, Fluconazole Etc.,) 5. Patients who are on drugs affecting cytochrome metabolism ( Protease inhibitors , Rifampicin , Ketoconazole etc.,) 6. Patients with significant dyselectrolytemia. 7. Old and frail patients, terminally ill patients who have less probability of being alive till the end of the study duration.

Design outcomes

Primary

MeasureTime frame
GI cancer pain is measured Numerical Rating Scale and compared between 2 groups.Timepoint: Upon OPD visits at Presentation, 1st week, 2nd week, and 4th week.

Secondary

MeasureTime frame
To evaluate the side effect profile of combination of low dose Methadone with Morphine and Morphine alone for pain management in Gastrointestinal cancers.Timepoint: Patients will be evaluated at 1 week, 2 week and 1 month.;To evaluate whether the addition of Low dose methadone with Morphine decreases the total opioid consumption.Timepoint: Patients will be evaluated at 1 week, 2 week and 1 month.

Countries

India

Contacts

Public ContactDr Sachidanand Jee Bharati

All India Institute of Medical Sciences, New Delhi

sacidadr@yahoo.co.in9968436042

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026